Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En fase IIB, randomiseret, dobbeltblind, placebokontrolleret undersøgelse af elismetrep (K-304) i behandlingen af ​​migræne

30. oktober 2026 opdateret af: TriGemX Bio, Inc.

En fase IIB, randomiseret, dobbeltblind, placebokontrolleret undersøgelse af elismetrep (K-304) i behandlingen af ​​migræne: En række doser vil blive evalueret

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

431

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35205
        • Central Research Associates, LLC (CRA) dba Flourish Research
      • Mobile, Alabama, Forenede Stater, 36608
        • AMR Mobile
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85710
        • Wake Research/ Tucson Neuroscience Research
    • California
      • Canoga Park, California, Forenede Stater, 91303
        • Hope Clinical Research
      • Encino, California, Forenede Stater, 91316
        • WR-PRI, LLC (Encino)
      • Huntington Beach, California, Forenede Stater, 92647
        • Marvel Clinical Research
      • La Mesa, California, Forenede Stater, 91942
        • Eximia Research - CA
      • Lemon Grove, California, Forenede Stater, 91945
        • Synergy San Diego
      • Newport Beach, California, Forenede Stater, 92660
        • WR-PRI, LLC (Newport Beach)
      • Oceanside, California, Forenede Stater, 92056
        • Excell Research, Inc.
      • Pomona, California, Forenede Stater, 91767
        • Empire Clinical Research
      • Riverside, California, Forenede Stater, 92503
        • Artemis Institute for Clinical Research - Riverside
      • San Diego, California, Forenede Stater, 89109
        • Acclaim Clinical Research
      • San Diego, California, Forenede Stater, 92103
        • Artemis Institute for Clinical Research - San Diego
      • Walnut Creek, California, Forenede Stater, 94598
        • Diablo Clinical Research, Inc.
      • West Hills, California, Forenede Stater, 91307
        • Focus Clinical Research
    • Connecticut
      • Cromwell, Connecticut, Forenede Stater, 06416
        • CT Clinical Research
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • DelRicht Research
      • Stockbridge, Georgia, Forenede Stater, 30281
        • Clinical Research Atlanta - Stockbridge
    • Idaho
      • Boise, Idaho, Forenede Stater, 83704
        • Northwest Clinical Trials
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60607
        • Cedar Crosse Research Center
      • Flossmoor, Illinois, Forenede Stater, 60422
        • Healthcare Research Network II, LLC
    • Kansas
      • Overland Park, Kansas, Forenede Stater, 66202
        • Collective Medical Research
      • Wichita, Kansas, Forenede Stater, 67207
        • Alliance for Multispecialty Research
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40213
        • L-MARC Research Center
    • Louisiana
      • Chalmette, Louisiana, Forenede Stater, 70043
        • Crescent City Headache & Neurology Center
      • New Orleans, Louisiana, Forenede Stater, 70115
        • DelRicht Research
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48104
        • Michigan Head Pain and Neurological Institute
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55402
        • Clinical Research Institute
    • Mississippi
      • Gulfport, Mississippi, Forenede Stater, 39503
        • DelRicht Research
    • Missouri
      • Hazelwood, Missouri, Forenede Stater, 63042
        • Healthcare Research Network
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, Forenede Stater, 89119
        • Las Vegas Clinical Trials
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87102
        • Albuquerque Clinical Trials, Inc.
    • New York
      • Amherst, New York, Forenede Stater, 14226
        • Dent Neurosciences Research Center
      • Manlius, New York, Forenede Stater, 13104
        • CNY Clinical Research
      • Rochester, New York, Forenede Stater, 14609
        • Rochester Clinical Research
      • Williamsville, New York, Forenede Stater, 14221
        • Upstate Clinical Research Associates LLC
    • North Carolina
      • Greensboro, North Carolina, Forenede Stater, 27405
        • Headache Wellness Center
      • High Point, North Carolina, Forenede Stater, 27260
        • Peters Medical Research
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45212
        • CTI Clinical Research Center
    • Oklahoma
      • Edmond, Oklahoma, Forenede Stater, 73034
        • OK Clinical Research, LLC
      • Oklahoma City, Oklahoma, Forenede Stater, 73102
        • Hightower Clinical
      • Tulsa, Oklahoma, Forenede Stater, 74133
        • DelRicht Research
      • Yukon, Oklahoma, Forenede Stater, 73099
        • Tekton Research
    • Oregon
      • Portland, Oregon, Forenede Stater, 97210
        • Summit Research Network
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
        • Lehigh Center for Clinical Research
      • Philadelphia, Pennsylvania, Forenede Stater, 19114
        • Clinical Research Philadelphia, LLC
      • Scottdale, Pennsylvania, Forenede Stater, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Forenede Stater, 15478
        • Frontier Clinical Research, LLC
      • West Chester, Pennsylvania, Forenede Stater, 19380
        • Atlas-Clinical
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29406
        • Clinical Trials of South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Chattanooga, Tennessee, Forenede Stater, 37421
        • WR-ClinSearch
      • Knoxville, Tennessee, Forenede Stater, 37909
        • AMR Knoxville (Formerly NOCCR)
      • Nashville, Tennessee, Forenede Stater, 37203
        • Clinical Research Associates, Inc.
    • Texas
      • Austin, Texas, Forenede Stater, 78745
        • Tekton Research
      • Austin, Texas, Forenede Stater, 78737
        • Donald J Garcia Jr, MD, PA
      • Dallas, Texas, Forenede Stater, 75251
        • FutureSearch Trials of Dallas, LP
      • Houston, Texas, Forenede Stater, 77024
        • Victorium Clinical Research LTD CO
      • Splendora, Texas, Forenede Stater, 77372
        • APD Clinical Research
      • Waxahachie, Texas, Forenede Stater, 75165
        • ClinPoint Trials
    • Utah
      • Ogden, Utah, Forenede Stater, 84405
        • Advanced Research Institute
    • Virginia
      • Newport News, Virginia, Forenede Stater, 23606
        • Health Research of Hampton Roads, Inc.
    • West Virginia
      • Morgantown, West Virginia, Forenede Stater, 26505
        • Frontier Clinical Research, LLC
    • Wisconsin
      • Kenosha, Wisconsin, Forenede Stater, 53144
        • Clinical Investigation Specialist

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.

  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.

  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).

  4. Meet the following requirements:

    1. Is a male OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

    3. Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.

    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of reproductive potential and:

    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)

      • intrauterine hormone-releasing system (IUS)

      • bilateral tubal occlusion

      • vasectomised partner

      • sexual abstinence

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

      • male or female condom with or without spermicide

      • cap, diaphragm or sponge with spermicide

      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.

  6. Participant is able to read, understand and complete the study questionnaires and diary.

  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.

  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.

  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.

  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).

  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.

  6. Participant was >50 years old at age of first migraine onset.

  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].

  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.

  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.

  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

  13. Has a history of human immunodeficiency virus disease.

  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and electrocardiogram (ECG) related

  15. Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.

  16. Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.

  17. Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.

  18. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.

  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.

  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.

  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.

  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.

  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.

  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.

  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected hypersensitivity to trial product(s) or related products.

  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.

  29. Has any surgery scheduled for the duration of the trial.

  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).

  31. Has previous participation in this trial. Participation is defined as signed informed consent.

  32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.

  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Elismetrep (K-304) Dose Level 1

Participants received a single dose of elismetrep 2 mg

Administered orally

Eksperimentel: Elismetrep (K-304) Dose Level 2

Participants received a single dose of elismetrep 5 mg

Administered orally

Eksperimentel: Elismetrep (K-304) Dose Level 3

Participants received a single dose of elismetrep 10 mg

Administered orally

Eksperimentel: Elismetrep (K-304) Dose Level 4

Participants received a single dose of elismetrep 20 mg

Administered orally

Placebo komparator: Placebo

Participants received a single dose of elismetrep-matched placebo

Administered orally

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pain Freedom
Tidsramme: 2 hours post-dose

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

2 hours post-dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Tidsramme: up to 7 days after administration of study therapy
up to 7 days after administration of study therapy
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Tidsramme: 2 hours post-dose

Assessed using the number of evaluable participants that reported the absence of their MBS

2 hours post-dose
Pain Relief
Tidsramme: 2 hours post-dose

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

2 hours post-dose
Freedom From Photophobia
Tidsramme: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

2 hours post-dose
Freedom From Phonophobia
Tidsramme: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

2 hours post-dose
Freedom From Nausea
Tidsramme: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

2 hours post-dose
The Probability of Requiring Rescue Medication
Tidsramme: 24 hours post-dose

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

24 hours post-dose
Sustained Pain Freedom
Tidsramme: From 2 to 24 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest

From 2 to 24 hours
Sustained Pain Relief
Tidsramme: From 2 to 24 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 24 hours
Sustained Pain Freedom
Tidsramme: From 2 to 48 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

From 2 to 48 hours
Sustained Pain Relief
Tidsramme: From 2 to 48 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Tidsramme: Up to 7 days after administration of study therapy

Serious adverse events were assessed in the Safety Analysis Set.

Up to 7 days after administration of study therapy

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. marts 2025

Primær færdiggørelse (Faktiske)

4. august 2025

Studieafslutning (Faktiske)

4. august 2025

Datoer for studieregistrering

Først indsendt

21. februar 2025

Først indsendt, der opfyldte QC-kriterier

25. februar 2025

Først opslået (Faktiske)

26. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • K-304 P001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .